Navigation Links
Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients

GOTEBORG, Sweden, October 2 /PRNewswire/ -- Calabar AB announced today that their Phase II repeated dose study in xerostomia ("dry mouth") patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to select a dose for evaluation in a succeeding Phase III efficacy study.

Xalieve(TM) is a gel containing the cholinesterase inhibitor physostigmine. It is administered locally in the mouth where physostigmine diffuses through the mucosa reaching the minor glands. By inhibiting cholinesterase, acetylcholine accumulates and the elevated concentrations stimulate the muscarinic receptors in the minor glands, improving saliva production. Unlike systemically administered drugs, the local route of administration limits adverse events.

"Xalieve(TM) offers a completely new approach in treating dry mouth and we are very excited about this Phase II study," said Mr. Fredrik Rook, VP Business Development of Calabar. "Xerostomia is not getting the attention it deserves. These patients are experiencing dramatic decrease in quality of life, such as difficulty in swallowing and speaking, and a burning sensation in the mouth. Xalieve(TM) has the possibility to radically improve the life of millions of people suffering from dry mouth."

About Calabar AB:

Calabar is a privately-held company committed to developing pharmaceutical products addressing the significant unmet needs of xerostomia "dry mouth". The company's product Xalieve(TM) is a locally administered formulation of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. The company is part of the Karolinska Development AB portfolio. For more information, please visit


VP Business Development,

Fredrik Rook,

+46-8-524-860-38, .

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
9. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
10. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
Breaking Medicine News(10 mins):